Breaking Down Zhejiang Huahai Pharmaceutical Co., Ltd. Financial Health: Key Insights for Investors

Zhejiang Huahai Pharmaceutical's recent financials paint a complex picture for investors: Q3 2025 revenue dropped to CNY 1.89 billion (a ‑10.70% year‑over‑year decline) with TTM revenue of CNY 8.71 billion as of Sept 30, 2025, even after a strong 2024 annual revenue of CNY 9.55 billion; profitability has softened-H1 2025 net income attributable to shareholders fell to CNY 409.49 million (net profit margin 9.07% vs. 14.68% a year earlier) while EPS slid to CNY 0.28 and trailing ROE eased to 12.28%-balance sheet metrics show total debt of CNY 2.35 billion with a debt‑to‑equity ratio of 77.95%, a current ratio of 1.62 and short‑term assets exceeding liabilities by CNY 2.1 billion, but operating cash flow plunged 65.25% in the first nine months of 2025 and the company reported a Q3 2025 net loss of CNY 29.13 million; valuation multiples sit at a trailing P/E of 29.10 and a P/S of 3.06 while market capitalization stood at CNY 26.62 billion on Dec 10, 2025, and risks from pricing pressure, rising R&D (up 54% YoY) and increased leverage are balanced against growth vectors like exports to 60+ countries, FDA certifications and ANDA approvals-read on to dissect revenue drivers, margins, liquidity, valuation and the strategic moves shaping near‑term investor outcomes

Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS) - Revenue Analysis

Recent top-line trends show a downshift after 2024's strong pace. Key reported figures:

• Primary cause of recent decline: intensified competition leading to pricing pressure across domestic and export markets.
• Product mix shifts and slower uptake in key generics/innovator licensing contributed to lower quarterly sales.
• Operational scale remains substantial: revenue/employee ~CNY 960.7k, indicating relatively high productivity per head despite revenue contraction.

Investors should note the divergence between 2024's YoY growth (CNY 9.55B, +14.91%) and the 2025 pullback reflected in both Q3 and TTM figures, which compresses valuation metrics and raises sensitivity to volume and pricing recovery.

Further context and investor focus areas are available here: Exploring Zhejiang Huahai Pharmaceutical Co., Ltd. Investor Profile: Who's Buying and Why?

Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS) - Profitability Metrics

• Net income attributable to shareholders (H1 2025): CNY 409.49 million (vs. CNY 748.57 million in H1 2024).
• Net profit margin (H1 2025): 9.07% (down from 14.68% in H1 2024).
• Operating margin (H1 2025): 18.51% (down from 20.68% in H1 2024).
• Earnings per share (EPS, H1 2025): CNY 0.28 (vs. CNY 0.52 in H1 2024).
• Trailing twelve-month ROE (as of Mar 31, 2025): 12.28% (down from 14.5% year-over-year).

• R&D impact: higher absolute R&D outlays reduced reported operating and net margins in H1 2025.
• Market dynamics: pricing pressure and competition in key therapeutic and generic segments weighed on top-line growth and margin recovery.

Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS) - Debt vs. Equity Structure

• Total debt (as of 2025-03-31): CNY 2.35 billion.
• Debt-to-equity ratio: 77.95%.
• Net debt-to-equity ratio (5-year trend): increased from 55.9% to 79.5%.
• Interest coverage ratio (EBIT / Interest): 4.4x.
• Common stock issued in H1 2025: CNY 591.5 million (to strengthen the balance sheet).
• Short-term asset surplus (Current assets - Current liabilities): CNY 2.1 billion.
• Long-term asset surplus (Non-current assets - Non-current liabilities): CNY 1.1 billion.

• Implications for creditors: moderate leverage with adequate interest coverage (4.4x) and positive long-term asset cushions.
• Implications for equity holders: net debt-to-equity rising to 79.5% signals increased financial risk over the past five years despite recent equity issuance of CNY 591.5m.
• Liquidity perspective: short-term assets exceed short-term liabilities by CNY 2.1bn, indicating operational liquidity to meet near-term obligations.

Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS) - Liquidity and Solvency

• Current ratio (31-Mar-2025): 1.62 - adequate short-term liquidity on a balance-sheet basis.
• Operating cash flow (first 9 months of 2025): CNY 652.39 million, down 65.25% YoY - significant deterioration in cash generation.
• Q3 2025 net result: net loss of CNY 29.13 million vs. net profit in Q3 2024 - indicating recent earnings pressure.
• Quick ratio: not disclosed; likely below 1 given net loss and negative cash flow, pointing to weaker immediate liquidity once inventories are excluded.
• Cash flow to debt ratio: described as insufficient, implying limited ability to cover debt principal from operating cash.
• Interest coverage ratio: 4.4x - the company can currently meet interest obligations, but coverage is moderate rather than comfortable.

Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS) - Valuation Analysis

• Trailing P/E (as of July 4, 2025): 29.10
• Forward P/E (as of July 4, 2025): 24.99
• Price-to-Book (P/B): 3.59
• Price-to-Sales (P/S): 3.06
• Enterprise Value-to-Revenue (EV/R): 3.53
• EV/EBITDA: 13.33
• Market capitalization (as of July 1, 2025): CNY 34.42 billion

• The gap between trailing and forward P/E (29.10 vs. 24.99) signals anticipated earnings growth or margin recovery.
• P/B of 3.59 and P/S of 3.06 show investors are willing to pay a premium for assets and revenue - consistent with a company viewed as having stable growth prospects.
• EV/EBITDA at 13.33 indicates moderate valuation multiples: neither deeply discounted nor exuberant compared with typical pharma sector ranges.
• Overall metrics align with industry averages, reflecting measured market confidence despite past financial headwinds.

Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS) Risk Factors

• Pricing pressures and intensified competition in domestic and international markets have compressed gross margins and limited pricing power.
• R&D spending rose sharply - a 54% year-over-year increase - which supports medium-to-long-term pipeline development but has reduced short-term profitability.
• Management expects net income for the first half of 2025 to decline roughly 40%-50% year-on-year, signaling near-term earnings weakness.
• Operating cash flow declined substantially, down 65.25% year-over-year for the comparable period, raising questions about cash sustainability and working capital management.
• The debt-to-equity ratio has increased over the past five years (see table), indicating rising financial leverage and greater sensitivity to interest rate and refinancing risk.
• The company's ongoing strategic transformation - portfolio adjustments, geographic expansion, and heavier R&D commitment - may create short-term execution risk and financial volatility.

• Cash-flow sensitivity: A 65.25% drop in operating cash flow for H1 year-on-year amplifies liquidity risk - especially if capex and R&D remain elevated.
• Leverage dynamics: The five-year rise in D/E to ~0.85 increases exposure to interest-rate moves and refinancing cycles; covenant terms and maturity ladder should be monitored.
• Earnings volatility: An expected H1 2025 net income decline of ~40%-50% underscores earnings cyclicality; investors should stress-test forecasts under slower revenue growth and continued margin compression.
• Execution risk from transformation: Strategic shifts (pipeline prioritization, market reorientation) can strain margins and working capital before benefits materialize.

Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS) - Growth Opportunities

• Export footprint: products sold to over 60 countries across Europe, the Americas, Asia and other regions, providing geographic diversification of revenue streams.
• Partner network: long-term collaborations with more than 500 pharmaceutical companies worldwide, enabling contract manufacturing, licensing and co-marketing opportunities.
• Therapeutic focus: leading manufacturer in cardiovascular and central nervous system (CNS) product categories, which remain high-demand segments globally.

• US FDA milestone: Zhejiang Huahai is the first Chinese pharmaceutical company to pass US FDA certification for finished pharmaceutical products, a credential that materially reduces market access barriers in the United States and enhances credibility with global buyers.
• ANDA approvals: the company has obtained ANDA approval(s) for self-developed products, enabling direct large-scale sales in the US generics market and recurring revenue potential from established therapeutic classes.

• API trade growth: ramping global API exports and sourcing partnerships expand margin improvement opportunities and lower supply-chain risk through diversification of both suppliers and customers.